NasdaqCM:IGIC
NasdaqCM:IGICInsurance

Does RBC’s Renewed Confidence in IGIC’s Underwriting Discipline Reveal a Durable Edge in Soft Markets?

RBC Capital Markets recently resumed coverage of International General Insurance Holdings, assigning an “Outperform” rating and emphasizing the insurer’s long-term track record of disciplined underwriting and consistent profitability in a softening market. The endorsement effectively spotlights IGIC’s cautious management style and underwriting strength as differentiators at a time when many peers face margin pressure. We’ll now examine how RBC’s renewed confidence in IGIC’s underwriting...
NYSE:VAC
NYSE:VACHospitality

How Marriott Vacations’ Dividend Hike and Buyback Extension Will Impact Marriott Vacations Worldwide (VAC) Investors

Marriott Vacations Worldwide recently announced that its Board of Directors increased the quarterly dividend to US$0.80 per share, payable on or around January 7, 2026, to shareholders of record as of December 24, 2025. This combination of a higher cash return and an extended share repurchase window underscores management’s focus on rewarding shareholders while exercising active capital management. Now we’ll examine how the dividend hike, alongside the extended buyback plan, may influence...
NasdaqGS:NCNO
NasdaqGS:NCNOSoftware

What nCino (NCNO)'s US$100 Million Buyback Amid Insight's Exit Means For Shareholders

Earlier in December 2025, nCino, Inc. announced that its Board of Directors had authorized a stock repurchase program of up to US$100 million, to be funded through existing cash, credit capacity and future cash flows. This new buyback comes as Insight Holdings Group fully exited its nCino position and broader technology-sector concerns about AI profitability weighed on investor sentiment. Against this backdrop of a major institutional exit, we’ll explore how nCino’s US$100 million buyback...
NasdaqGS:INBX
NasdaqGS:INBXBiotechs

Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates

Inhibrx Biosciences (INBX) just gave investors a fresh look at its oncology pipeline, highlighting progress in INBRX-106 combo trials with Keytruda and ozekibart studies that could support meaningful FDA conversations in 2026. See our latest analysis for Inhibrx Biosciences. That steady clinical drumbeat has been mirrored in the market, with the share price at $83.09 after a 7.09 percent 1 month share price return and a powerful 444.85 percent year to date share price return, contributing to...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

Is First Bancorp (FBNC) Overvalued After Its Recent Share Price Strength?

First Bancorp (FBNC) has quietly turned in a strong stretch, with shares up about 10 % over the past month and roughly 23 % this year, outpacing many regional banking peers. See our latest analysis for First Bancorp. That steady climb reflects growing confidence after First Bancorp’s resilient fundamentals, with a roughly 23 % year to date share price return and a solid multi year total shareholder return indicating that momentum is building rather than fading. If First Bancorp’s run has you...
NasdaqGS:ALGT
NasdaqGS:ALGTAirlines

A Look at Allegiant Travel (ALGT) Valuation After Its New Global Hotel Loyalty Partnership

Allegiant Travel (ALGT) just rolled out a new loyalty lever, teaming up with Rocket Travel by Agoda to launch Allegiant Hotels and let Allways Rewards members earn or redeem points on global hotel stays. See our latest analysis for Allegiant Travel. The move comes as Allegiant Travel’s 30 day share price return of 35.9 percent and 90 day share price return of 36.8 percent signal improving momentum, even though year to date share price performance remains negative and the five year total...
NYSE:PHR
NYSE:PHRHealthcare Services

Phreesia (PHR): Reassessing Valuation After Back-to-Back Profits and Upgraded 2026–2027 Outlook

Phreesia (PHR) just delivered its second straight profitable quarter, along with higher revenue and an upgraded outlook for 2026 and 2027, signaling a business that is finally scaling more efficiently. See our latest analysis for Phreesia. Despite the solid execution, Phreesia's share price has struggled this year, with a year to date share price return of negative 35.29 percent and a one year total shareholder return of negative 32.11 percent. This suggests sentiment is still catching up to...
NYSE:TDS
NYSE:TDSWireless Telecom

Assessing Telephone and Data Systems’ Valuation After Its Expanded Credit Agreement and Added Debt Capacity

Telephone and Data Systems (TDS) just rewired its main credit agreement, extending the maturity date, stripping out certain SOFR interest add ons, and opening up an extra $300 million of secured and unsecured borrowing capacity. See our latest analysis for Telephone and Data Systems. The refinancing lands at a time when TDS’s share price has quietly rebuilt confidence, with an 11.05% year to date share price return and a striking 308.65% three year total shareholder return. This points to...
NYSE:SPG
NYSE:SPGRetail REITs

Simon Property Group (SPG): Reassessing Valuation After Insider Buying and Taubman Integration Updates

Simon Property Group (SPG) just drew fresh attention after Director Randall Lewis bought more shares, extending a steady streak of insider buying. Together with upbeat Taubman integration commentary, this is reshaping how investors are sizing up the REIT. See our latest analysis for Simon Property Group. Against this backdrop, Simon’s share price has quietly trended higher, with a solid year to date share price return and an even stronger multiyear total shareholder return suggesting momentum...
NasdaqGS:PI
NasdaqGS:PISemiconductor

Assessing Impinj (PI) Valuation After Q3 Beat and New Gen2X Anti‑Counterfeiting Launch

Impinj (PI) just cleared a key hurdle in its third quarter, beating earnings and revenue expectations while rolling out new Gen2X features designed to tackle counterfeiting and messy tag data across large enterprise deployments. See our latest analysis for Impinj. The upbeat quarter appears to be breathing life back into the story, with a 1 month share price return of nearly 15% helping offset a weaker 3 month patch and backing up a 5 year total shareholder return near 291%. This suggests...
NasdaqGS:NWE
NasdaqGS:NWEIntegrated Utilities

NorthWestern Energy (NWE): Is The Recent Share Price Momentum Justified By Its Valuation?

NorthWestern Energy Group (NWE) has quietly outpaced many utility peers this year, with the stock up about 31% over the past year and roughly 24% year to date, catching income-focused investors attention. See our latest analysis for NorthWestern Energy Group. The latest leg higher has been driven more by a gradual shift in risk perception than by any single headline. The 90 day share price return of 17.23 percent and the 1 year total shareholder return of 31.10 percent suggest that momentum...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Ligand Pharmaceuticals (LGND) Valuation After Its 2026 Royalty-Focused Earnings Outlook Drives Investor Interest

Ligand Pharmaceuticals (LGND) just put numbers around its 2026 outlook, projecting total revenue between $245 million and $285 million, with the bulk expected from royalty streams rather than product or contract sales. See our latest analysis for Ligand Pharmaceuticals. That forward look seems to be resonating with investors, with the share price now at $194.59 and a strong year to date share price return of 79.48 percent alongside a hefty 3 year total shareholder return of 190.30 percent,...
NYSE:BFLY
NYSE:BFLYMedical Equipment

Butterfly Network (BFLY): Valuation Check After Midjourney Deal, Insider Buying and Compass AI Launch

Butterfly Network (BFLY) is back on traders radar after a three way catalyst: a fresh licensing and co development deal with Midjourney, a director share purchase, and the launch of its Compass AI platform. See our latest analysis for Butterfly Network. Those catalysts have arrived against a backdrop of a sharp turnaround in sentiment. Butterfly’s 30 day share price return of 60.9 percent and 90 day gain of 67.7 percent contrast with a still modest 1 year total shareholder return of 1.6...
NasdaqGM:RILY
NasdaqGM:RILYCapital Markets

B. Riley Financial (RILY): Evaluating Valuation After a Sharp Earnings Rebound and Profitability Turnaround

B. Riley Financial (RILY) just swung from a huge loss to solid profitability in its latest second quarter report, with revenue more than doubling and earnings per share flipping sharply back into positive territory. See our latest analysis for B. Riley Financial. The strong earnings rebound comes after a volatile stretch, with a sharp 1 day share price return of minus 17.5 percent and a 90 day share price return of minus 34.1 percent. The 3 year total shareholder return of minus 84.4 percent...
OTCPK:DIDI.Y
OTCPK:DIDI.YTransportation

DiDi (OTCPK:DIDI.Y): Valuation Check After Robotaxi Trials, Self‑Driving Fundraise, Buyback and IPO Settlement Progress

DiDi Global (OTCPK:DIDI.Y) is back in focus after launching 24/7 fully unmanned robotaxi trials in Guangzhou, raising fresh capital for its self-driving arm, completing a major buyback, and nearing closure on a sizeable U.S. IPO lawsuit settlement. See our latest analysis for DiDi Global. Despite the legal overhang easing and the robotaxi push signalling long term growth ambitions, DiDi Global’s 30 day share price return of 3.18 percent contrasts with a still weak 90 day share price return of...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix (CRMD): Reassessing Valuation After Strong Multi‑Year Share Price Performance

CorMedix (CRMD) has quietly delivered a strong year so far, and investors are starting to ask whether the recent share performance lines up with the company’s growth profile and risk-reward trade off. See our latest analysis for CorMedix. With the share price now at $11.45, CorMedix has seen a punchy year to date, with a 39.29% year to date share price return and a standout 3 year total shareholder return of 189.87%. This suggests momentum has been building as investors reassess its growth...
NYSE:CI
NYSE:CIHealthcare

What Cigna Group (CI)'s Rising Medical Costs And Securities Probe Mean For Shareholders

Recently, BofA Securities highlighted The Cigna Group’s exposure to commercial health insurance and its scaled pharmaceutical platform, while Levi & Korsinsky began investigating potential federal securities law violations following Cigna’s disclosure of a higher Healthcare medical cost ratio that could pressure future profitability. This combination of optimism around pharmacy-driven earnings growth and scrutiny of rising medical costs underscores the tension between Cigna’s long-term...
NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos (LDOS): Valuation Check After Hiring AI Veteran Ted Tanner Jr. as Chief Technology Officer

Leidos Holdings (LDOS) just made a strategically interesting move, naming AI veteran Theodore Ted Tanner Jr. as its next chief technology officer. Investors are already asking what this could mean for the stock. See our latest analysis for Leidos Holdings. That AI focused CTO hire lands at an interesting moment, because while the 1 month share price return is slightly negative, the year to date share price return of 26.6 percent and a three year total shareholder return near 79.5 percent show...
NYSE:VYX
NYSE:VYXSoftware

How Investors Are Reacting To NCR Voyix (VYX) Reaffirming POS Lead And Growing Recurring Revenue

NCR Voyix recently reported that it has retained its No. 1 global position in POS software installations across retail, reclaimed the top spot in new restaurant deployments, and reinforced its leadership in Grocery+ and convenience sectors. Alongside this industry leadership, the company’s latest quarterly results showed stronger recurring software and services revenue with improved profitability margins, reflecting progress in its platform-led, AI-enabled digital commerce strategy. Now,...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

BioCryst (BCRX) Valuation After FDA Expands ORLADEYO Access for Young Hereditary Angioedema Patients

BioCryst Pharmaceuticals (BCRX) just picked up a meaningful catalyst, with the FDA clearing an oral pellet version of Orladeyo for children aged 2 to under 12 with hereditary angioedema, opening a newly addressable niche. See our latest analysis for BioCryst Pharmaceuticals. Despite this catalyst, BioCryst’s 1 year total shareholder return of around minus 2 percent and a 3 month share price return of roughly minus 10 percent suggest momentum has been fading, even as management pursues the...
NYSE:RRC
NYSE:RRCOil and Gas

Range Resources (RRC): Evaluating Valuation After Four Straight Earnings Beats and Effective Natural Gas Hedging

Range Resources (RRC) just extended its streak of outperforming earnings expectations, backed by effective natural gas hedging that is helping smooth out commodity price swings and, in turn, lifting investor confidence in the story. See our latest analysis for Range Resources. Even after today’s 1 day share price return of 2.82 percent, Range’s stock is still down on a 1 month share price basis. However, its 5 year total shareholder return of 399.01 percent shows the longer term momentum...
NasdaqCM:SBET
NasdaqCM:SBETHospitality

Is SharpLink Gaming (SBET) Quietly Recasting Its Core Identity Around Institutional Ethereum Treasury Management?

SharpLink Gaming, Inc. recently completed a planned leadership transition appointing Joseph Chalom as CEO, while expanding its institutional-grade Ethereum treasury platform by more than doubling its ETH holdings and updating corporate bylaws. By increasing institutional ownership to over 30% and emphasizing Ethereum treasury management, the company is repositioning itself as a specialized, crypto-focused treasury operator within the broader digital asset ecosystem. Next, we’ll examine how...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Syndax Pharmaceuticals (SNDX): Assessing Valuation After Key ASH Data on Revuforj and Niktimvo

Syndax Pharmaceuticals (SNDX) is back on traders radar after showcasing fresh data on its FDA approved cancer drugs Revuforj and Niktimvo at the high profile ASH hematology meeting in Orlando. See our latest analysis for Syndax Pharmaceuticals. The momentum around these ASH updates lines up with a strong run in the stock, with Syndax delivering a roughly 44% year to date share price return and a 59% total shareholder return over the last year, even as multi year total shareholder returns...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Expedia Group (EXPE): Reassessing Valuation After Strong Q3 Earnings Beat and Improving Growth Outlook

Expedia Group (EXPE) is back on investors radar after a stronger than expected third quarter, where earnings and demand outpaced forecasts and helped drive a 17.6% jump in the stock over the past month. See our latest analysis for Expedia Group. That surge has capped a strong run, with a roughly 16% 30 day share price return and a robust 1 year total shareholder return of about 62%, suggesting momentum is clearly building as investors reassess Expedia Group’s growth prospects and perceived...